Overview

Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome

Status:
Terminated

Trial end date:
2016-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adolescent and adult subjects with Prader-Willi Syndrome.

Phase:

Phase 3

Details

Lead Sponsor:

Zafgen, Inc.

Treatments:

CKD732